4Novotny VMJ, Van Doom R,Witvliet Ml),et al. Occurrence d alloge- neic HLA and non - HLA antibodies after transfusion of prestorage filtered platelet and red blood cells:a prospective study. Blood,1995, 85 (7) : 1736 - 1741.
3Novotny VM.Prevention and management of platelet transfusion refractoriness[J].Vox Sang,2002,82(6):516-520.
4Rebulla P.Refractoriness to platelet transfusion[J].Curr Opin Hematol,2002,9(6):516-520.
5Fabris F,Soini B,Sartori R,et al.Clinical and laboratory factors that affect the post-transfusion platelet increment[J].Transfus Sci,2000,23(1):63-68.
6Gelb AB,Leavitt AD.Crossmatch-compatible plat-elets improve corrected count increments in patients who are refractory to randomly selected platelets[J].Transfusion,1997,37(6):624-630.
7Ca rcia- Suarez J ,Prieto A, Reyes R, et al. The clinical outcome of autoimmune thrombocytopenic purpura patient is related to their T cell immunoodeficiency. Br J Haematol, 1993; 84: 464～ 470
8Sample JW, Bruce S, Freedman J. SuppreSsed natural killer cell activity in patient with chronic autoimmune thrombocytopenic purpura. AM J heamatol, 1991;37:258～262
9曹俊泽.成分输血指南[M].上海:复旦大学上海医科大学联合出版社,2001:51-54.
10NOVOTNY V M J.Prevention and management of platelet transfusion refractoriness[J].vox song,1999,76:1.
